Alzforum: What We Know, What We Don't Know


	Current Papers
	ARF Recommends
	Milestone Papers
	Search All Papers
	Search Comments


	Research News
	Drug News
	Conference News


	AD Hypotheses
		SWAN Knowledge Base
		Current Hypotheses
		Hypothesis Factory
	Forums
		Live Discussions
		Virtual Conferences
		Interviews
	Enabling Technologies
		Workshops
		Research Tools
	Compendia
		AlzGene
		AlzRisk
		Antibodies
		Mutations
		Research Models
	Resources
		Bulletin Boards
		Conference Calendar
		Grants
		Jobs


	Overview
	Diagnosis/Genetics
	Research
	News
	Profiles
	Clinics


	Companies
	Tutorial
	Drugs in Clinical Trials


	About Alzheimer's
		FAQs
	Diagnosis
		Clinical Guidelines
		Tests
		Brain Banks
	Treatment
		Drugs and Therapies
	Caregiving
		Patient Care
		Support Directory
		AD Experiences
	Expert Opinion
		Ask the Expert


	Member Directory
	Researcher Profiles
	Institutes and Labs


	Mission
	ARF Team
	ARF Awards
	Advisory Board
	Sponsors
	Partnerships
	Fan Mail
	Support Us

Home: Research: Forums: Live Discussions

What We Know, What We Don't Know

back to table

	What we know	What we don’t know
6.	60 percent of people diagnosed with MCI go on to be diagnosed with AD	Can those with AD be identified while still at the MCI stage?

	Comments

	Comment by: Jurgen Claassen (Disclosure)
	Submitted 8 May 2007	Posted 1 June 2007
	I would be more interested in the 40 percent who do not progress to clinical AD. What is the cause of their cognitive impairment if not AD? Or even more interesting, why did AD not progress from the MCI stage. Do these individuals have disease-limiting phenomena? View all comments by Jurgen Claassen

	Comment by: Alvin Lyckman
	Submitted 8 April 2008	Posted 10 April 2008
	This statistic is not meaningful without knowing what percentage of non-MCI people go on to develop AD in the same time frame. View all comments by Alvin Lyckman

	Comment by: Alvin Lyckman
	Submitted 15 April 2008	Posted 22 April 2008
	In addition, the significance of MCI to AD and age-related dementias in general requires knowing the prevalence of MCI. Since AD is clearly not inevitable, with or without prior MCI, I agree with Jurgen Classen that further distinguishing the non-progressors will provide critical insight. However, we have yet to establish the epidemiological relationships between sporadic AD and MCI versus non-pathologic aging. View all comments by Alvin Lyckman

	Submit a Comment

Cast your vote and/or make a comment on this page.

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name
*Last Name
Country or Territory:
*Login Email Address
*Password
*Confirm Password
Remember my Login and Password?

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:

*Enter the verification code you see in the picture below:

This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:	Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.




			Print this page Email this page Alzforum News Text size Share & Bookmark Del.icio.us Digg Facebook Google Newsvine








			Compared to cancer, why do so few people with AD participate in drug trials?

				Doctors fail to point out opportunities

				Caregivers don't want added bother

				Informed consent is tricky

				People don't understand the need

				People can't easily access

				All of the above








			Archived Polls







			Antibodies Cell Lines Collaborators Papers Research Participants